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The multi-kinase inhibitor sorafenib (SOR) is clinically important in the treatment of hepatocellular 
and renal cancers and undergoes CYP3A4-dependent oxidation in liver to the pharmacologically active 
N-oxide metabolite (SNO). There have been reports that kinase inhibitors such as SOR may precipitate 
pharmacokinetic interactions with coadministered drugs that compete for CYP3A4-mediated 
biotransformation, but these occur non-uniformly in patients. Clinical evidence also indicates that SNO 
accumulates in serum of some patients during prolonged SOR therapy. In this study undertaken in 
hepatic microsomes from individual donors, we assessed the possibility that SNO might contribute to 
pharmacokinetic interactions mediated by SOR. Enzyme kinetics of CYP3A4-mediated midazolam 1′
-hydroxylation in individual human hepatic microsomes were analyzed by nonlinear regression and 
appropriate replots. Thus, SNO and SOR were linear-mixed inhibitors of microsomal CYP3A4 activity 
(Kis 15 ± 4 and 33 ± 14 μM, respectively). To assess these findings, further molecular docking studies 
of SOR and SNO with the 1TQN crystal structure of CYP3A4 were undertaken. SNO elicited a larger 
number of interactions with key amino acid residues located in substrate recognition sequences of 
the enzyme. In the optimal docking pose, the N-oxide moiety of SNO was also found to interact directly 
with the heme moiety of CYP3A4. These findings suggest that SNO could contribute to 
pharmacokinetic interactions involving SOR, perhaps in individuals who produce high circulating 
concentrations of the metabolite. 
 
INTRODUCTION 
Multi-kinase inhibitors have significantly improved cancer treatment by selectively targeting signal 
transduction pathways that promote tumorigenesis. Sorafenib (SOR) is an important drug that is used 
in the treatment of liver and renal carcinomas (1,2; Fig. 1). Although SOR is better tolerated than 
conventional cytotoxic agents, a number of adverse events with these drugs, including dose-limiting 
toxicities such as the hand-foot syndrome and other dermal toxicities, and pharmacokinetic drug–
drug interactions (DDIs) have been reported in some patients (1–4). Adverse events with SOR may 
require interruptions to dosage regimen or even to the termination of therapy. The pharmacokinetic 
behavior of SOR during therapy is complex. There is a non-linear relationship between dose and 
systemic exposure, and both SOR and its major activemetabolite SOR N-oxide (SNO) accumulate in 
serum with repeated doses (3,5–8); the extent of accumulation varies between patients. 
Biotransformation enzymes, especially the hepatic cytochrome P450 (CYP) mixed-function oxidases, 
are major factors that influence the rate of drug elimination. The quantitatively important human 
hepatic CYP3A4 mediates the oxidation of SOR to its primary metabolites, including SNO (9,10). To 
maximize their anti-cancer actions, kinase inhibitors like SOR are being used increasingly in 
combination with other oncology drugs, some of which are also substrates for CYP3A4 (3,4,8,11,12). 
Clinical studies have reported that the clearance of coadministered drugs may be impaired in some 




Fig. 1. Structures of SOR and its major metabolite SNO 
 
Personalized medicine aims to tailor the selection and dosage of drugs to the individual patient. 
Individuals in whom  CYP3A4 oxidation is high might generate SNO more efficiently, which could lead 
to higher serum concentrations of the metabolite. In this study, we assessed the capacity of SOR and 
its major metabolite SNO to inhibit CYP3A4- mediated midazolam 1′-hydroxylation in human liver 
microsomes. The principal finding to emerge from kinetic studies was that SNO was ~ 2-fold more 
effective than the parent drug as an inhibitor of CYP3A4 activity. From docking studies, SNO and SOR 
were found to interact with key amino acid residues in the catalytic site of the enzyme that are 
associated with ligand binding; there was a larger number of interactions for SNO than for SOR. In 
addition, the N-oxide oxygen atom of SNO was in close proximity to the heme moiety in CYP3A4, 
consistent with its capacity to inhibit the enzyme. These findings suggest that SNO could contribute to 
clinically significant DDIs that have been observed in some patients during SOR therapy.  
 
MATERIALS AND METHODS 
Drugs and Chemicals 
SOR (4-[4-([4-chloro-3-(trifluoromethyl)phenyl] carbamoylamino)phenoxy]-N-methylpyridine-2-
carboxamide) and SNO were synthesized as described by Gillani et al. (13). Midazolam and all 
biochemicals were obtained from Sigma- Aldrich (Castle Hill, NSW, Australia). 1′-Hydroxymidazolam 
was from Cerilliant (Round Rock, TX, USA). Microsomal fractions containing cDNA-directed CYP3A4 
expressed in insect cells (Supersomes) were obtained from BD Biosciences (North Ryde, NSW, 
Australia). Solvents and general reagents were from LabScan (Lomb Scientific, Taren Point, NSW, 
Australia) or Ajax Chemicals (Sydney, NSW, Australia). 
Liver Donors and Preparation of Microsomal Fractions  
Experiments in human liver microsomes were approved by ethics committees of the Western Sydney 
Area Health Service and the University of Sydney, according to the Declaration of Helsinki. Liver 
segments from 16 individual donors were available for the study and were obtained through the 
Queensland and Australian Liver Transplant Programs (Princess Alexandria Hospital, Brisbane, 
Queensland, and Royal Prince Alfred Hospital, Sydney, NSW, Australia, respectively). Liver tissue was 
from the normal margin during orthotopic liver transplantation or resection of liver tumors and was 
perfused with cold Viaspan solution within 15 min of surgical removal (DuPont, Wilmington, DE, USA), 
and then transferred to liquid nitrogen for storage. Liver microsomes were prepared by differential 
ultracentrifugation (14), and protein content was quantified as described previously (15).  
Midazolam and SOR Biotransformation by Human Liver Microsomes 
Microsomal CYP3A-mediated midazolam 1′-hydroxylation was determined as described previously 
(16). Incubations (37°C, 100 μg protein, 5 μM midazolam) in 0.1 M potassium phosphate buffer (pH 
7.4, 0.5 mL) were initiated with NADPH (1 mM). Linearity of product formation in incubations was 
established. After 5 min, reactions were terminated (formic acid; 0.1%; 1.5 mL) and loaded onto SPE 
cartridges (Bond Elut C18; Agilent Technologies, Mulgrave, VIC, Australia). Cartridges were washed 
with ammonium acetate (10 mM, 1 mL) and eluted with methanol (2 × 1 mL); diazepam was the 
internal standard. Midazolam and its 1′-hydroxy-metabolite were quantified by LC-MS/MS (Finnigan 
MAT TSQ 7000 system using electrospray ionization in the positive ion mode; San Jose, CA, USA) after 
separation on an Alltima C18 5 μ column (150 × 2.1 mm I.D.; HiChrome, Reading, Berks, UK).  
Microsomal SOR biotransformation was determined as described previously (10). Incubations (37°C, 
75 μg protein, 75 μM SOR) in 0.1 M potassium phosphate buffer (pH 7.4, 0.25 mL) were initiated with 
NADPH (1 mM); SOR was added in 2.5 μL DMSO, which did not significantly affect product formation. 
Linearity of product formation in incubations was established. After 20 min, reactions were 
terminated (acetonitrile; 0.5 mL), the precipitate was removed by centrifugation, and the supernatant 
was dried under nitrogen; the internal standard was SOR-methyl-d3. SOR and SNO were quantified by 
LC-MS/MS after separation on an XTerra MS C18 3.5 μ column (150 × 2.1 mm I.D.; Waters, Rydalmere, 
NSW, Australia). 
Inhibition of CYP3A4-Dependent Midazolam 1′-Hydroxylation by SOR and SNO 
Initial inhibition studies in human hepatic microsomes (n = 3 individual livers) were undertaken at a 
midazolam concentration of 1 μM. This is within the range of total midazolam concentrations in 
patient plasma (17,18). Total concentrations were used because this improved DDI assessments 
with hydrophobic drugs (like midazolam and SOR) that may accumulate in liver (19). Kinetic studies 
were then conducted over a wider range of substrate concentrations (0.5–10 μM midazolam) that 
spanned the Km. Kinetic data  were analyzed by non-linear regression of 1′-hydroxymidazolam 
formation (V) as a function of midazolam (S) concentration, accompanied by statistical analysis (r2 of 
all regression lines; GraphPad Prism 5; San Diego, CA, USA). Data were analyzed further by 
Lineweaver–Burk and Dixon plots and appropriate replots to characterize the mode of inhibition (20). 
Ki values were obtained from the x-intercept of Dixon slope replots.  
Computational Details of the Docking of Ligands into the Active Site of CYP3A4  
X-ray crystal structures for CYP3A4 were reported in 2004 by two groups (21,22), and several crystal 
structures are now available. The 1TQN structure of CYP3A4 was used in the present molecular 
docking analysis because this has been used in previous studies with SOR (10,23). The CYP3A4 
structure was prepared by including the unresolved residues (282–285) in the 1TQN structure, H-
atoms, and Kollman all atom charges using the Bipolymer module of SYBYL (version X-2.1, Certara, 
Princeton, NJ, USA). The unresolved residues in the N- and C-termini of the X-ray structure, which are 
distant from the catalytic site, were excluded from the analysis. The three-dimensional coordinates 
(sdf format) of SOR and SNO and midazolam were obtained from the Pubchem server 
(https://pubchem.ncbi.nlm.nih.gov/). All molecular modeling was performed using SYBYL, installed on 
a Red Hat Linux 6.9 OS workstation. Gasteiger–Huckel partial atomic charges (24) were assigned, and 
energy minimization was done using Powell’s conjugate gradient method in conjunction with a Tripos 
5.2 force field (25,26). A minimum energy difference of 0.001 kcal/mol was set as the convergence 
criterion. 
Molecular docking experiments were conducted using Surflex-Dock docking suite (27). The binding 
site for ligand docking was defined by protomol, which identified the hemebinding site as the principal 
site. Molecular docking of SOR and SNO was performed in the presence and absence of midazolam. 
The resulting binding poses were ranked according to the total score (SYBYL). For the study of ternary 
complexes, two strategies were adopted. In the first approach, midazolam was docked in the CYP3A4 
binding site, followed by docking of SOR or SNO. Alternately, SOR or SNO was docked in the CYP3A4 
binding site, followed by the docking of midazolam.  
Statistics 
Data are expressed throughout as means ± SEM of individual estimates as indicated.  
 




Interindividual Variation in SNO Formation and Midazolam 1′-Hydroxylation in Human Liver 
Microsomes  
Liver tissue from 16 individual donors was available for the present study. Limited information on 
demographic factors and drug histories was available for eight of the donors and is shown in Table I. 
The age range was 6–69, and seven of the donors were female. Two of the liver donors had received 
glucocorticoids, which are potential CYP3A4 inducers—prednisone (HL8) and dexamethasone 
(HL10)—while another donor (HL12) received the CYP3A4 substrate simvastatin; however, detailed 
information on dosage regimen was not available. SNO formation was measured in 14 livers (HL1–
HL14) and varied over a 6.5- fold range (0.06–0.39 nmol/mg protein/min; Fig. 2). In comparison, 
CYP3A-mediated midazolam 1′-hydroxylation varied 7.8-fold in the same fractions (0.23–1.8 
pmol/mg protein/min; Fig. 2). 
 
Fig. 2. Interindividual variation in midazolam 1′-hydroxylation and SOR N-oxidation to SNO in human 
liver microsomes (n = 14). 
 
 
Comparative Inhibition of Microsomal CYP3A4-Dependent 
1′-Hydroxylation of Midazolam by SOR and Its Major Oxidized Metabolite SNO The Km for midazolam 
was 2.1 ± 0.2 μM in human liver microsomes, while Vmax values were in the range 50–447 pmol 1′-
hydroxymidazolam/min/mg protein (n = 4 livers: HL5, HL13, HL15, and HL16); these values are 
compatible with those reported previously (28,29). In initial studies, IC50s were determined for SOR 
and its major metabolite SNO against the CYP3A4-catalyzed 1′-hydroxylation of midazolam (1 μM), 
which is within the range of total plasma concentrations of the drug reported in clinical studies (17,18). 
SNO exhibited an IC50 of 20 ± 1 μM (n = 3 individual livers), whereas 50% inhibition was not attained 
at the highest test concentration of SOR (50 μM). We corroborated these findings using cDNA-
expressed human CYP3A4. IC50s of 13 ± 1 μM and 20 ± 2 μM were obtained for SNO and SOR, 
respectively, at a midazolam concentration of 3 μM. Because SNO appeared to be a more effective 
inhibitor than the parent drug, kinetic studies were undertaken to evaluate the interaction in greater 
detail. In the case of SOR, the livers HL5, HL13, and HL15 were used in experiments and HL5, HL15, 
and HL16 were used to evaluate SNO; representative analyses are shown in Figs. 3 and 4. The data 
were fitted by alternate models of inhibition (GraphPad Prism 5). The optimal fit was obtained for 
linear-mixed inhibition kinetics as described by the Henri–Michaelis–Menten equation: 
 
Lineweaver–Burk and Dixon plots with appropriate replots were constructed to verify the mode of 
inhibition as linear-mixed (20). From the primary Lineweaver–Burk plots, the point of intersection of 
the lines was above the x-axis and to the left of the y-axis for both SOR and SNO (Figs. 3b and 4b), 
while the Dixon slope replots were linear and intercepted the x-axis to the left of the origin (Figs. 3e 
and 4e). The Ki in the case of SNO was 15 ± 4 μM, and 33 ± 14 μM for SOR. The factor α describes the 
extent to which the equilibrium constants Km and Ki are altered by inhibitor and substrate, 
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Fig. 3. Kinetic analysis of the inhibition of human microsomal CYP3A4-mediated midazolam 1′-
hydroxylation by SOR. a Michaelis–Menten plot; key to SOR concentrations: (filled circles) 0 μM, (filled 
triangles) 10 μM, (filled squares) 30 μM, (empty circles) 50 μM. b Lineweaver– Burk plot. c 
Lineweaver–Burk slope (LB slope) replot. d Dixon plot; key to midazolam concentrations: (filled circles) 
1 μM, (filled triangles) 3 μM, (filled squares) 5 μM, (empty circles) 10 μM. e Dixon slope replot. A 




Fig. 4. Kinetic analysis of the inhibition of human microsomal CYP3A4-mediated midazolam 1′-
hydroxylation by SNO. a Michaelis–Menten plot: key to NOX concentrations: (filled circles) 0 μM, (filled 
triangles) 1 μM, (filled squares) 10 μM, (empty circles) 30 μM. (empty triangles) 50 μM. b Lineweaver–
Burk plot. c Lineweaver–Burk slope (LB slope) replot. d Dixon plot; key to midazolam concentrations: 
(filled circles) 1 μM, (filled triangles) 3 μM, (filled squares) 5 μM, (empty circles) 10 μM. e Dixon slope 
replot. A representative analysis conducted in one of three separate microsomal fractions is shown. 
 
 
Fig. 5. Michaelis–Menten equilibria showing CYP3A4-inhibitor/substrate complex formation and linear 
mixed-type reversible inhibition of CYP3A4-dependent midazolam 1′-hydroxylation. [inhibitor] 
refers to either SOR or SNO (as shown in Figs. 3 and 4, respectively). 
 
Computational Modeling 
Molecular docking was undertaken to evaluate the interactions between CYP3A4 (1TQN structure) 
and both SOR and SNO in greater detail (Fig. 6).Docking was also performed with alternate CYP3A4 
crystal structures (not shown); the binding conformations of SOR/SNO were found to be near identical 
using these structures. The energetically favorable binding mode of SOR showed that the distance 
between the atom in SOR that preferentially undergoes oxidation (the heterocyclic nitrogen atom of 
the pyridine ring, to form SNO) and the CYP3A4 heme iron was 3.3 Å (Fig. 6a). This is compatible with 
the reported distance between the heme and oxidizable atom in the CYP3A4-bromoergocryptine 
crystal structure (30), and within the 6 Å limit suggested by de Graaf et al. (31). In comparison, SNO 
was docked in a catalytically favourable orientation with a distance of 2.1 Å between the oxygen atom 
of the N-oxide group and the heme iron (Fig. 6b). This finding is also in accord with the recent finding 
that SNOundergoes CYPmediated reduction at the N-oxide moiety to regenerate SOR (13).  
Docking studies identified aromatic π-π interactions between SOR/SNO and the residues Phe 108 and 
Phe 220 within the active site of CYP3A4. The structures were stabilized by further interactions in the 
catalytic center, including polar interactions between SOR/SNO and Asp 76, Arg 105, Arg 212, and Glu 
374, and hydrophobic interactions with Ile 120, Ile 301, Ala 305, Thr 309, Ile 369, and Ala 370. It is 
noteworthy that there were additional interactions between SNO and residues within the CYP3A4 
catalytic site (Fig. 6b) due to differences in the binding modes for SNO and SOR (Fig. 6c). Thus, the 
docked pose of SNO shows direct Hbonding between the diaryl ether oxygen and Ser 119, while two 
of the fluorines in the aromatic CF3 group are potential H-bond acceptors for Arg 106 and Thr 224, 
respectively. Furthermore, halogen-π interactions between the Cl atom of SNO and Phe 57 were 
observed. In addition, the aromatic residues Phe 215 and Phe 304 are involved in π-stacking 
interactions with the CF3-substituted aromatic system and hydrophobic interactions with the central 
phenyl ring of SNO, respectively. Although binding scores should be interpreted with caution (32), the 
total score of the docked SNO was somewhat greater than that for SOR (9.8 versus 8.2; SYBYL), which 
suggests that the interaction of CYP3A4 with SNO is of higher affinity than that with SOR (33).  
 
Fig. 6. Docked poses of SOR and SNO in the catalytic site of CYP3A4. a SOR, b SNO, and c overlay of 
SOR and SNO. Key amino acid residues involved in binding interactions are numbered 
 
In the presence of a bound midazolam molecule, SNO and SOR were docked inefficiently; the principal 
site of metabolism was distant from the heme iron (> 10 Å; not shown). When SOR was docked within 
the active site of CYP3A4, midazolam was bound > 23 Å from the heme. Similar findings were obtained 
when SNO was docked into the CYP3A4 structure when midazolam was already present. 
 
DISCUSSION 
The multi-kinase inhibitor SOR precipitates pharmacokinetic DDIs with certain coadministered drugs 
that are CYP3A4 substrates in some, but not all, patients who receive combination therapy. The 
underlying mechanism of these DDIs is unclear, but such information is important for the development 
of strategies that minimize DDIs in order to optimize SOR therapy. CYP3A4 is the major catalyst in the 
oxidation of SOR to SNO (Vmax/Km 9.4 pmol/pmol CYP/h/ μM), whereas CYP3A5 was ~ 13-fold less 
efficient (Vmax/Km 0.74 pmol/pmol CYP/h/μM; 10). The inhibitory actions of SOR toward CYP3A4-
mediated midazolam 1′-hydroxylation are reportedly enhanced in NADPH-supplemented human 
liver microsomes (34,35). Although inhibition was timedependent, mechanism-based inhibition could 
not be established. In this study, we assessed the possibility that SNO—the primary oxidized and 
pharmacologically active metabolite of SOR—may contribute to the inhibition of CYP3A4 activity. 
Indeed, Giri et al. reported that another N-oxide metabolite—voriconazole N-oxide—was an effective 
inhibitor of CYP3A4 (IC50 8.7 μM; 36), and there are other CYP-mediated drug metabolites that have 
been shown to be more effective inhibitors than the parent drugs. These include not only reactive 
metabolites generated by CYP oxidation of alkylamino, methylenedioxyphenyl, thionosulfur, phenolic, 
and unsaturated moieties (37–43) but also major isolable metabolites that elicit reversible inhibition 
of CYPs (44–46). 
From kinetic studies, the Ki for SNO against midazolam 1′-hydroxylation was 15 ± 4 μM and the Km 
for midazolam was ~ 2 μM. Therefore, CYP3A4 has an ~ 7.5-fold greater affinity for midazolam than 
for SNO. In comparison, the higher Ki value for SOR (33 ± 14 μM) indicates that the affinity of CYP3A4 
for midazolam is ~ 16-fold that of SOR. Whereas SOR has been found previously to be a moderate 
inhibitor of the enzyme (23), to our knowledge, the metabolite SNO has not been evaluated in detail 
as a CYP3A4 inhibitor. The present findings suggest that SNO is a major metabolite of SOR that 
mediates reversible CYP3A4 inhibition. 
The pharmacokinetics of SOR are complex and exhibit  extensive interindividual variation (5,6). The 
area under the serum concentration versus time curve (AUC) for SOR, which reflects systemic drug 
exposure, was increased in patients who received prolonged therapy with the drug (4– 6). This could 
reflect impaired CYP-dependent clearance by metabolites such as SNO that has also been shown to 
accumulate in serum in a number of patients (7,8). Thus, SOR and SNO accumulated several fold in 
three of eight patients after 12 days of SOR treatment, compared with maximal serum concentrations 
at day 7 (7). Indeed, the maximal serum concentration (Cmax) of SNO reached 8.5 μM in one patient, 
which is close to the Ki for CYP3A4 inhibition that was estimated in the present study. Several other 
studies also reported variable SNO pharmacokinetics in patient serum over the approximate range 1–
5 μM (4,6,8,47,48). SOR has been used increasingly in combination with other anticancer agents, but 
these have the potential to elicit pharmacokinetic DDIs and increase the likelihood of adverse effects. 
The combination of doxorubicin (60 mg/m2) and SORat several dose levels was generally well 
tolerated, but some patients who received the highest dose of SOR exhibited significant increases in 
the Cmax and AUC of doxorubicin (11). Interpatient variation in these parameters was pronounced. 
More recently, the AUC0–24 for docetaxel (100 mg/m2) was found to be increased on average by 54% 
following administration of 200 mg SOR twice daily, and up to 80% at the standard therapeutic dose 
of 400 mg twice daily(3). These authors also reported that SOR inhibited docetaxel hydroxylation in 
microsomes with an IC50 of ~ 17 μM. Similarly, the Cmax of vinorelbine was increased to ~ 1.6-fold of 
control in patients with metastatic breast cancer who were also administered SOR (8). Further, in 
some colorectal cancer patients who received the SOR/irinotecan combination, exposures to 
irinotecan and its active metabolite SN38 were increased over those with irinotecan alone, suggesting 
that SOR and/or SNO might inhibit irinotecan biotransformation that is mediated in part by CYP3A4 
(4,12). These studies all recommended caution in the management of patients receiving combinations 
of SOR and oncology drugs that require CYP3A4 for biotransformation. 
SNO and SOR were linear mixed-type inhibitors of microsomal midazolam 1′-hydroxylation. The 
parameter α indicates the extent to which inhibitor and substrate decrease the apparent affinity of 
the enzyme for substrate and inhibitor, respectively (20). In the present study, the values of α for SNO 
and SOR were in the range 11–15, indicating that these molecules significantly decrease the capacity 
of CYP3A4 to interact with midazolam. The active site of unliganded CYP3A4 has a large volume (~ 950 
Å3; 21). However, the active site also appears to have multiple binding pockets that undergo 
significant conformational changes on binding of substrates; this accounts for structural diversity and 
cooperative interactions between substrates (49–53). To evaluate the present kinetic findings further, 
we undertook molecular modeling of the SOR/SNO-CYP3A4 interactions using the 1TN crystal 
structure that has been used previously to analyze SOR binding (10,23). Docking studies with CYP3A4 
identified aromatic π-π interactions between both SOR and SNO and the residues Phe 108 and Phe 
220, polar interactions with Asp 76, Arg 105, Arg 212, and Glu 374, and hydrophobic interactions with 
Ile 120, Ile 301, Ala 305, Thr 309, Ile 369, and Ala 370. These hydrophobic residues were found 
previously to be important in midazolam binding (54). Figure 7 shows the location of the residues in 
CYP3A4 that were involved in interactions with SOR and SNO in relation to the protein helical domains 
and β-sheets, and also the substrate recognition sequences (SRS) that comprise the active center of 
the enzyme (55). Amino acids that interacted with both SOR and SNO were located in SRS-1 (which 
spans residues 101–123), SRS-2 (which spans 204–216), SRS-4 (which spans 294–312), and SRS-5 (368–
376), but not SRS-3 or SRS-6. In SRS-1, three residues were involved in SOR/ SNO interactions (Phe 
108, Ile 120, and Arg 105), one was located in SRS-2 (Arg 212), three were in SRS-4 (Ala 305, Ile 301, 
and Thr 309), and three were in SRS-5 (Glu 374, Ile 369, and Ala 370). Phe 220 and Arg 76 were also 
involved in SOR/ SNO interactions but were outside SRS regions.  
 
 
Fig. 7. Amino acid sequence of CYP3A4 showing the location of residues implicated in binding 
interactions with both SOR and SNO (asterisks) and SNO alone (crosses). Bars indicate the locations of 
helical domains (italicized letters) and β-sheets (italicized numbers). Amino acid residues in SRS 
regions are shown in boxes. 
 
From kinetic studies, the interaction of CYP3A4 with SNO was found to be of higher affinity than that 
with SOR. In accord with these findings, additional binding interactions emerged from the SNO-
CYP3A4 docking analysis, including H-bonding with Ser 119, Arg 106, and Thr 224, halogen-π 
interactions between the Cl atom of SNO and Phe 57, a π-stacking interaction between the 
trifluorophenyl ring and Phe 215, and hydrophobic interactions with Phe 304. Two of these additional 
interactions involved residues in SRS-1 (Ser 119 and Arg 106), one involved the SRS-2 residue Phe 215 
and one involved the SRS-4 residue Phe 304. The non-SRS residues Phe 57 and Thr 224 also contributed 
to the SNO-CYP3A4 interaction. Previous studies identified roles for several of these additional 
residues in the interaction ofCYP3A4 with other ligands. Thus, Ser 119 was associated with H-
bonding/polar interactions with ritonavir analogues (56), aflatoxin B1 (51), and ketoconazole (52); Arg 
212 and Thr 224 were important for the orientation of bromoergocryptine in the CYP3A4 active site 
(30) and Phe 304 was also involved in aflatoxin B1 binding (52). Like SNO, these ligands are effective 
CYP3A4 inhibitors and/or substrates.  
The present docking analysis also offers an explanation to account for the recently reported NADPH-
dependent aerobic reduction of SNO to SOR that is mediated by human CYPs (13). The mechanism of 
this reaction has been proposed to involve direct interaction of the N-oxygen atom in SNO with the 
ferrous CYP heme iron (13). It is now apparent that the heme N-oxide oxygen interaction is stabilized 
by multiple interactions with amino acid residues in SRS regions that are located within the active 
center of  CYP3A4 (Fig. 6b). Subsequent reduction by an electron from NADPH delivered via the 
NADPH-CYP reductase could then facilitate nitrogen–oxygen bond cleavage in SNO, with transfer of 
the oxygen atom to the heme iron, and liberation of SOR and water; similar reactions have been 
reported for certain other drug and xenobiotic N-oxides (57,58).  
Taken together, the present findings suggest that interindividual differences in SNO formation and its 
accumulation in serum could contribute to variableDDIs in patients who receive SOR. Additional 
evidence for the capacity of SNO to elicit in vivo DDIs with SOR could be obtained using SOR-treated 
CYP3A4-transgenic mice (59), which could enable increased concentrations of the metabolite in serum 
to be generated provided an appropriate dosage regimen is used. Such studies could complement 
aspects of the present study. However, it would now be of interest to assess SNO production directly 
in patients who are receiving SOR. Indeed, monitoring of serum SNO concentrations over time may 




The multi-kinase inhibitor SOR precipitates pharmacokinetic DDIs in some, but not all, patients. In the 
present study, the major SOR metabolite SNO was found to be a more potent mixed-type inhibitor of 
CYP3A4 than the parent drug. Docking studies identified a number of binding interactions between 
SOR and SNO and amino acid residues in the active site of the enzyme. The larger number of 
interactions in the docking of SNO, as well as the direct ligation of the N-oxide moiety to the CYP heme 
iron, accounts for its greater inhibitory potency toward CYP3A4. This finding also provides a potential 
explanation for the recent report that SNOundergoes CYP-mediated reduction back to SOR. The 
overproduction of the inhibitory metabolite SNO, and its accumulation in serum of some patients, 
could contribute to the interindividual variation in pharmacokinetic DDIs involving SOR. 
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